Three scientists — Mary Brankow, Fred Ramsdell, and Simon Sakaguchi — have been awarded the Nobel Prize for a groundbreaking discovery that fundamentally explains how the immune system distinguishes between “self” and “non-self” cells, as well as why this process can fail and lead to autoimmune diseases.
For decades, one of the greatest mysteries in immunology was how the body’s powerful defense system avoids attacking its own tissues. The laureates’ work provided a decisive answer by uncovering the crucial role of regulatory T cells, or Tregs — a specialized group of immune cells responsible for suppressing excessive or misguided immune responses. These cells act as the immune system’s internal “brakes,” ensuring balance and preventing self-destruction.
Посмотреть эту публикацию в Instagram
At the heart of their discovery lies the FOXP3 gene, which the researchers identified as essential for the development and proper function of regulatory T cells. When FOXP3 is damaged or does not function correctly, the immune system loses its ability to regulate itself. As a result, immune cells may begin attacking the body’s own tissues, triggering severe autoimmune reactions. This finding helped explain the biological roots of immune tolerance and why its breakdown can be so devastating.
The implications of this discovery are vast. It has laid the scientific foundation for developing new therapies targeting conditions such as type 1 diabetes, rheumatoid arthritis, multiple sclerosis, and complications following organ transplantation. In addition, understanding how to control immune suppression has opened promising avenues in cancer treatment, where carefully “releasing the brakes” on the immune system can help it recognize and destroy tumor cells.
Посмотреть эту публикацию в Instagram
Perhaps most importantly, this breakthrough has made it possible to precisely modulate immune responses — strengthening them when needed and calming them when they become harmful. By reshaping how scientists view immune regulation, the discovery paves the way for next-generation, personalized immunotherapies that could transform the treatment of autoimmune diseases, cancer, and beyond.
